Circulating endocannabinoids in insulin sensitive vs. Insulin resistant obese postmenopausal women. A MONET group study

Obesity

Volumn 22, Issue 1, 2014, Pages 211-216

  Abdulnour, Joseph ^a   Yasari, Siham ^a   Rabasa Lhoret, Rémi ^b,c   Faraj, May ^b,c   Petrosino, Stefania ^d   Piscitelli, Fabiana ^d   Prud'Homme, Denis ^a   Di Marzo, Vincenzo ^d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; BIOLOGICAL MARKER; CHOLESTEROL; ENDOCANNABINOID; GLUCOSE; INSULIN; N OLEOYLETHANOLAMINE; PALMIDROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIET THERAPY; ENDOCANNABINOID BLOOD LEVEL; FAT FREE MASS; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN RESISTANT OBESITY; INSULIN SENSITIVE OBESITY; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LEAN BODY WEIGHT; LIPID METABOLISM; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MIDDLE AGED; OBESITY; PHENOTYPE; POSTMENOPAUSE; RESISTANCE TRAINING; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ARACHIDONIC ACIDS; BODY COMPOSITION; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; ENDOCANNABINOIDS; ETHANOLAMINES; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLYCERIDES; HUMANS; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; MIDDLE AGED; OBESITY; OLEIC ACIDS; PALMITIC ACIDS; POLYUNSATURATED ALKAMIDES; POSTMENOPAUSE; TRIGLYCERIDES; WEIGHT LOSS;

EID: 84892364262     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20498     Document Type: Article

References (31)

1. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP,. The continuing epidemics of obesity and diabetes in the United States. J Am Med Assoc 2001; 286: 1195-1200.
2. Meigs JB, Wilson PW, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006; 91: 2906-2912.
3. Hamer M, Stamatakis E,. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab 2012; 97: 2482-2488.
4. Primeau V, Coderre L, Karelis AD, et al. Characterizing the profile of obese patients who are metabolically healthy. Int J Obes (Lond) 2011; 35: 971-981.
5. Cote M, Matias I, Lemieux I, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007; 31: 692-699.
6. Bluher M, Engeli S, Kloting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55: 3053-3060.
7. Engeli S, Bohnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54: 2838-2843.
8. Matias I, Gonthier MP, Orlando P, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006; 91: 3171-3180.
9. Di Marzo V,. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 2008; 51: 1356-1367.
10. Tibirica E,. The multiple functions of the endocannabinoid system: A focus on the regulation of food intake. Diabetol Metab Syndr 2010; 2: 5.
11. Nam DH, Lee MH, Kim JE, et al. Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice. Endocrinology 2012; 153: 1387-1396.
12. D'Eon TM, Pierce KA, Roix JJ, Tyler A, Chen H, Teixeira SR,. The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids. Diabetes 2008; 57: 1262-1268.
13. Perkins JM, Davis SN,. Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment. Curr Diab Rep 2008; 8: 12-19.
14. Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008; 168: 1609-1616.
15. Matias I, Gonthier MP, Petrosino S, et al. Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. Br J Pharmacol 2007; 152: 676-690.
16. Di Marzo V, Verrijken A, Hakkarainen A, et al. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol 2009; 161: 715-722.
17. Brochu M, Malita MF, Messier V, et al. Resistance training does not contribute to improving the metabolic profile after a 6-month weight loss program in overweight and obese postmenopausal women. J Clin Endocrinol Metab 2009; 94: 3226-3233.
18. DeFronzo RA, Tobin JD, Andres R,. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am. J. Physiol. 1979; 237: E214-E223.
19. Karelis AD, Faraj M, Bastard JP, et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab 2005; 90: 4145-4150.
20. Friedewald WT, Levy RI, Fredrickson DS,. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
21. Annuzzi G, Piscitelli F, Di Marino L, et al. Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. Lipids Health Dis 2010; 9: 43.
22. Brochu M, Mathieu ME, Karelis AD, et al. Contribution of the lean body mass to insulin resistance in postmenopausal women with visceral obesity: A monet study. Obesity 2008; 16: 1085-1093.
23. Saavedra LE,. Endocannabinoid system and cardiometabolic risk. Clin Pharmacol Ther 2007; 82: 591-594.
24. Ginsberg HN, Woods SC,. The endocannabinoid system: Potential for reducing cardiometabolic risk. Obesity (Silver Spring) 2009; 17: 1821-1829.
25. Di Marzo V,. Targeting the endocannabinoid system: To enhance or reduce? Nat Rev Drug Discov 2008; 7: 438-455.
26. Di Marzo V, Cote M, Matias I, et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: Associations with changes in metabolic risk factors. Diabetologia 2009; 52: 213-217.
27. Pillarisetti S, Alexander CW, Khanna I,. Pain and beyond: fatty acid amides and fatty acid amide hydrolase inhibitors in cardiovascular and metabolic diseases. Drug Discov Today 2009; 14: 1098-1111.
28. Mitchell VA, Jeong HJ, Drew GM, Vaughan CW,. Cholecystokinin exerts an effect via the endocannabinoid system to inhibit GABAergic transmission in midbrain periaqueductal gray. Neuropsychopharmacology 2011; 36: 1801-1810.
29. Bermudez-Silva FJ, Cardinal P, Cota D,. The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. J Psychopharmacol 2012; 26: 114-124.
30. Heyman E, Gamelin FX, Aucouturier J, Di Marzo V,. The role of the endocannabinoid system in skeletal muscle and metabolic adaptations to exercise: potential implications for the treatment of obesity. Obes Rev 2012; 13: 1110-1124.
31. Lindborg KA, Teachey MK, Jacob S, Henriksen EJ,. Effects of in vitro antagonism of endocannabinoid-1 receptors on the glucose transport system in normal and insulin-resistant rat skeletal muscle. Diabetes Obes Metab 2010; 12: 722-730.